Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies

PLoS One. 2016 May 26;11(5):e0155674. doi: 10.1371/journal.pone.0155674. eCollection 2016.

Abstract

The purpose of this work is to develop a mathematical model of energy balance and body weight regulation that can predict species-specific response to common pre-clinical interventions. To this end, we evaluate the ability of a previously published mathematical model of mouse metabolism to describe changes in body weight and body composition in rats in response to two short-term interventions. First, we adapt the model to describe body weight and composition changes in Sprague-Dawley rats by fitting to data previously collected from a 26-day caloric restriction study. The calibrated model is subsequently used to describe changes in rat body weight and composition in a 23-day cannabinoid receptor 1 antagonist (CB1Ra) study. While the model describes body weight data well, it fails to replicate body composition changes with CB1Ra treatment. Evaluation of a key model assumption about deposition of fat and fat-free masses shows a limitation of the model in short-term studies due to the constraint placed on the relative change in body composition components. We demonstrate that the model can be modified to overcome this limitation, and propose additional measurements to further test the proposed model predictions. These findings illustrate how mathematical models can be used to support drug discovery and development by identifying key knowledge gaps and aiding in the design of additional experiments to further our understanding of disease-relevant and species-specific physiology.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Body Composition / drug effects
  • Body Weight / drug effects*
  • Body Weight / physiology
  • Caloric Restriction*
  • Cannabinoid Receptor Antagonists / pharmacology*
  • Energy Intake
  • Energy Metabolism / drug effects*
  • Male
  • Models, Theoretical*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors

Substances

  • Cannabinoid Receptor Antagonists
  • Receptor, Cannabinoid, CB1

Grants and funding

JS, WCT, TAP, DOS, TSM, and CJM were employees of Pfizer Inc. during the completion and/or analyses of these studies. At the time the research was conducted, JRH was an employee of Pfizer Inc.; JRH currently is an employee of Novartis Institutes of Biomedical Research. Pfizer Inc. has provided all funding for these studies and was responsible for the study design, data collection and analysis, decision to publish, and preparation of the manuscript.